A universal aptamer-based sensing strategy is proposed using DNA modified nanocarriers and Resistive Pulse Sensing (RPS) for the rapid (≤20 min) and label free detection of small molecules. The surface…
In this work, a surface plasmon resonance (SPR)-based assay for the quantification of antineoplastic drug irinotecan in human plasma samples has been developed for the first time. The selective…
Watch as Dr David Bunka, Aptamer Group CTO, details how BLI is used within Aptamer Group’s screening and validation processes to identify the best aptamer and Optimer™ reagents, with…
The anticancer drug imatinib is often involved in therapeutic drug monitoring (TDM) studies aimed at improving the treatment of several forms of leukemia and gastrointestinal stromal tumors (GIST). To…
Cystic fibrosis (CF) is one of the most lethal autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). It is estimated that…
Antibiotics have been widely used in human medicine, aquaculture and agriculture to treat serious infectious diseases. However, overuse and misuse of antibiotics in some areas have contributed to the…
The challenge Small molecules such as antibiotics, drugs, toxins and food additives are often perceived as difficult targets to obtain a suitable affinity ligand. The development of rapid,…
19th December 2018 This month: Aptamer Group data on selective cell based biomarker aptamers The year in review, from new product launches to company accolades Interesting applications in international…
